Dyne Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Selling, General & Admin	62.48	31.4	28.2	28.72	13.45	Upgrade
Research & Development	281.41	210.76	142.76	121.31	45.2	Upgrade
Operating Expenses	343.89	242.16	170.96	150.03	58.65	Upgrade
Operating Income	-343.89	-242.16	-170.96	-150.03	-58.65	Upgrade
Interest Expense	-	-	-	-	-0.4	Upgrade
Interest & Investment Income	26.92	7.64	2.92	0.74	0.06	Upgrade
Currency Exchange Gain (Loss)	-0.49	-1.39	-0.02	-	-	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-	-0.45	Upgrade
EBT Excluding Unusual Items	-317.45	-235.91	-168.07	-149.28	-59.44	Upgrade
Gain (Loss) on Sale of Investments	0.04	-0.02	-0.03	-0.01	-	Upgrade
Pretax Income	-317.42	-235.94	-168.1	-149.29	-59.44	Upgrade
Net Income	-317.42	-235.94	-168.1	-149.29	-59.44	Upgrade
Net Income to Common	-317.42	-235.94	-168.1	-149.29	-59.44	Upgrade
Shares Outstanding (Basic)	94	60	52	51	14	Upgrade
Shares Outstanding (Diluted)	94	60	52	51	14	Upgrade
Shares Change (YoY)	57.74%	14.83%	2.13%	253.54%	489.30%	Upgrade
EPS (Basic)	-3.37	-3.95	-3.23	-2.93	-4.13	Upgrade
EPS (Diluted)	-3.37	-3.95	-3.23	-2.93	-4.13	Upgrade
Free Cash Flow	-294.75	-188.89	-156.71	-123.18	-47.67	Upgrade
Free Cash Flow Per Share	-3.13	-3.17	-3.02	-2.42	-3.31	Upgrade
EBITDA	-342.21	-240.49	-169.28	-148.94	-57.95	Upgrade
D&A For EBITDA	1.67	1.67	1.68	1.09	0.7	Upgrade
EBIT	-343.89	-242.16	-170.96	-150.03	-58.65	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q